Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone.
about
Recent advances in the management of acromegalyCurrent therapies and mortality in acromegalyCombined treatment of somatostatin analogues with pegvisomant in acromegalyUse of Pegvisomant in acromegaly. An Italian Society of Endocrinology guidelineClinical applications of somatostatin analogs for growth hormone-secreting pituitary adenomasLong-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes.The role of primary pharmacological therapy in acromegaly.Frequency of multiple endocrine neoplasia type 1 in a group of patients with pituitary adenoma: genetic study and familial screening.Octreotide long-acting repeatable for acromegaly.Management options for persistent postoperative acromegaly.Investigational therapies for acromegaly.Lanreotide autogel(®): a review of its use in the treatment of patients with acromegaly.Lanreotide autogel in acromegaly - a decade on.Pasireotide for the treatment of acromegaly.The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis.The role of combination medical therapy in the treatment of acromegaly.Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly.Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY.Increasing Frequency of Combination Medical Therapy in the Treatment of Acromegaly with the GH Receptor Antagonist Pegvisomant.
P2860
Q26766199-9BD69EC5-D397-4531-BDDE-003142E90E2CQ26776238-C119C9AE-3C7C-4A3A-840C-69D807169C7CQ26776366-C068625A-C790-4404-9F00-CCB344BA5A1BQ34277844-3B3B95AB-C92E-4316-944E-1249D26DBC7BQ34658946-A0998585-FD68-4F7E-8159-9C59A2832D17Q36964536-BF05F745-3D2D-43E1-88C5-1C116C734F67Q37531005-082E22A1-15F8-4671-B3CA-59526772C024Q37531060-0DEDBE47-58A3-4BE6-BC22-4E9019D9D88EQ37990556-18C7434C-3FDC-4226-AF6E-3B808D76472EQ38049832-AFB1B210-1770-42D7-9488-2C947C5C5546Q38111437-A5433BB6-C70F-415F-8AF6-7F949AADE3E4Q38246440-18223A71-840E-450C-9669-F1B967F5B8A8Q38259409-E58BA268-57FC-41D8-96AB-13B2A3753E19Q38710873-5F061B89-F2A7-4F0F-922E-EDA94C180F58Q38924730-85C67AA9-E0C5-48C3-842E-BE9D4CE9F9CDQ38927318-E11FB8D4-7246-45F5-B8A1-C0B0F04EF76BQ39687911-B58688DC-42B4-4478-A13D-E147717ADC81Q40339066-33C5299E-A51C-474D-8709-C6A24F7E2A2EQ49681753-34BDA9F9-6D3B-48D9-A0C8-F37C7303615C
P2860
Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Coadministration of lanreotide ...... by somatostatin analogs alone.
@ast
Coadministration of lanreotide ...... by somatostatin analogs alone.
@en
type
label
Coadministration of lanreotide ...... by somatostatin analogs alone.
@ast
Coadministration of lanreotide ...... by somatostatin analogs alone.
@en
prefLabel
Coadministration of lanreotide ...... by somatostatin analogs alone.
@ast
Coadministration of lanreotide ...... by somatostatin analogs alone.
@en
P2093
P50
P356
P1476
Coadministration of lanreotide ...... by somatostatin analogs alone.
@en
P2093
Aart-Jan van der Lely
Pascal Birman
Philippe Caron
Sebastian Neggers
P304
P356
10.1530/EJE-10-0867
P577
2010-12-10T00:00:00Z